The world's largest vaccine manufacturer, the Serum Institute of India (SII), has sought the Drugs Controller General of India's (DCGI) permission to conduct a small domestic trial of the Novavax coronavirus vaccine that was found to be 89.3% effective in a UK trial, its Chief Executive Officer Adar Poonawalla told news agency Reuters on Friday. A mid-stage trial of its coronavirus vaccine in South Africa, where a troubling new variant of the deadly virus is common, showed 60% effectiveness among people who did not have HIV. Last year in September, Novavax had announced its deal with the world's largest vaccine manufacturing firm SII in order to produce 2 billion doses of coronavirus vaccines. The company also said that it plans to initiate clinical testing of these new vaccines in the second quarter of this year. With agency inputsSubscribe to Mint Newsletters * Enter a valid email * Thank you for subscribing to our newsletter.

Source: Mint January 29, 2021 04:52 UTC